Development
NeuroOne Medical Technologies Corporation
NMTC
$0.5817
-$0.0073-1.24%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -13.47M | -11.86M | -10.10M | -9.39M | -8.92M |
| Total Depreciation and Amortization | 222.10K | 199.30K | 170.20K | 144.70K | 129.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.23M | 1.20M | 1.25M | 1.21M | 1.22M |
| Change in Net Operating Assets | -1.19M | -2.43M | -284.50K | -627.60K | -761.90K |
| Cash from Operations | -13.20M | -12.89M | -8.97M | -8.66M | -8.33M |
| Capital Expenditure | -409.70K | -384.10K | -392.70K | -307.60K | -225.20K |
| Sale of Property, Plant, and Equipment | 7.50K | 7.50K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.00M | 3.03M | 57.10K | -942.90K | -2.94M |
| Cash from Investing | 2.60M | 2.65M | -335.60K | -1.25M | -3.17M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9.85M | 8.59M | 2.55M | 928.30K | 0.00 |
| Repurchase of Common Stock | -133.10K | -119.50K | -110.90K | -98.70K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.09M | -1.07M | -234.70K | -183.30K | -16.00K |
| Cash from Financing | 8.62M | 7.40M | 2.21M | 646.30K | -16.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.99M | -2.84M | -7.09M | -9.27M | -11.52M |